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Background
Oncolytic viruses are promising alternative cancer thera-
pies that can cause anti-cancer immunity. We found
Delta-24-RGD, an oncolytic adenovirus currently under-
going Phase I clinical trial in patients with recurrent glio-
blastomas, induced anti-glioma immunity in an
immunpcompetent mouse model. We hypothesized that
the anti-cancer immunity mediated by the virus could be
augmented through expressing the immune co-stimulator
OX40 ligand (OX40L) by the virus to enhance the anti-
gen-presenting function of the cancer cells.
Methods
Thus we constructed Delta-24-RGDOX which included an
OX40L-expressing cassette in the backbone of Delta-24-
RGD. The new virus expressed OX40L efficiently in cul-
tured cancer cells and in implanted glioma cells in mice
while kept the same replication efficiency as Delta-24-
RGD.
Results
Like its precedessor Delta-24-RGD, Delta-24-RGDOX
induced immunogenic cell death in glioma cells. Impor-
tantly, compared to Delta-24-RGD, Delta-24-RGDOX
induced enhanced anti-glioma activity in immunocompe-
tent glioma models (means: 28.5 versus 17 days, P < .0001)
but not in an immunodeficient model. Since glioma cells
expressed high levels of PD-L1, we combined Delta-24-
RGDOX with anti-PD-L1 antibody. Impressively,
it resulted in 100% long-term survival in the treated mice
while the virus alone only induced 25% long-term
survival (P = 0.001). Further studies revealed that
Delta-24-RGDOX induced higher levels of lymphocyte
infiltration at the tumor sits (P < .001), greater anti-tumor
activity of the lymphocytes (P < .05) and proliferation of
tumor-associated antigen specific lymphocytes (P = .0002)
than Delta-24-RGD.
Conclusions
Collectively, our data demonstrate that oncolytic viruses
carrying immune co-stimulatory ligands and its combina-
tion with antibodies mainly targeted to cancer cells may
constitute powerful and safer alternatives to the antibo-
dies and other strategies targeting immune checkpoints
in cancer therapy and warrant the development of clini-
cal trials in cancer patients in the near future.
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